Harnessing the immune system in acute myeloid leukaemia

被引：88

作者：

Austin, Rebecca ^{[1
]}

Smyth, Mark J. ^{[1
,2
]}

Lane, Steven W. ^{[1
,2
,3
]}

机构：

[1] QIMR Berghofer Med Res Inst, 300 Herston Rd, Herston, Qld 4006, Australia

[2] Univ Queensland, Sch Med, Brisbane, Qld 4072, Australia

[3] Royal Brisbane & Womens Hosp, Canc Care, Brisbane, Qld, Australia

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2016年 / 103卷

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

Acute myeloid leukaemia; Cancer immunosurveillance; Immunoediting; Neo-antigens; Immunotherapy; Immune checkpoints; Immune suppression; WT1 PEPTIDE VACCINATION; GENE-EXPRESSION PROFILES; NATURAL-KILLER-CELLS; TUMOR PROTEIN-1 WT1; REGULATORY T-CELLS; CHIMERIC ANTIGEN RECEPTORS; ACUTE MYELOGENOUS LEUKEMIA; CLASS-I EXPRESSION; STEM-CELLS; INDOLEAMINE 2,3-DIOXYGENASE;

D O I：

10.1016/j.critrevonc.2016.04.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute myeloid leukaemia (AML) is an aggressive blood cancer caused by the proliferation of immature myeloid cells. The genetic abnormalities underlying AML affect signal transduction pathways, transcription factors and epigenetic modifiers. In solid tumours, it is emerging that the genetic landscape of the tumour has a direct effect on the anti-tumour immune responses and response to immunotherapeutic treatment. However, there remains little information as to whether genetic abnormalities affect anti leukemic immune responses. This review discusses current knowledge of AML antigens and immune responses to AML with a particular focus on the role of T cells and natural killer cells. Understanding immune responses to AML has implications for the development and use of immunotherapies to treat AML patients with distinct genetic abnormalities. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：62 / 77

页数：16

共 257 条

[1] Vaccines as consolidation therapy for myeloid leukemia [J].

Alatrash, Gheath ;

Molldrem, Jeffrey J. .

EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (01) :37-50

[2] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[3] Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia [J].

Anguille, S. ;

Van Tendeloo, V. F. ;

Berneman, Z. N. .

LEUKEMIA, 2012, 26 (10) :2186-2196

[4] Interferon-α in acute myeloid leukemia: an old drug revisited [J].

Anguille, S. ;

Lion, E. ;

Willemen, Y. ;

Van Tendeloo, V. F. I. ;

Berneman, Z. N. ;

Smits, E. L. J. M. .

LEUKEMIA, 2011, 25 (05) :739-748

[5]

[Anonymous], 2015, Cancer Discov, V5, pOF13, DOI 10.1158/2159-8290.CD-RW2015-049

[6] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[7] Immune checkpoint blockade in hematologic malignancies [J].

Armand, Philippe .

BLOOD, 2015, 125 (22) :3393-3400

[8] Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity [J].

Armstrong, TD ;

Clements, VK ;

Martin, BK ;

Ting, JPY ;

OstrandRosenberg, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6886-6891

[9] Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis [J].

Aurelius, Johan ;

Thoren, Fredrik B. ;

Akhiani, Ali A. ;

Brune, Mats ;

Palmqvist, Lars ;

Hansson, Markus ;

Hellstrand, Kristoffer ;

Martner, Anna .

BLOOD, 2012, 119 (24) :5832-5837

[10] Haematological malignancies: at the forefront of immunotherapeutic innovation [J].

Bachireddy, Pavan ;

Burkhardt, Ute E. ;

Rajasagi, Mohini ;

Wu, Catherine J. .

NATURE REVIEWS CANCER, 2015, 15 (04) :201-215

← 1 2 3 4 5 6 7 8 9 10 →